Pricing Log in Create free account

Crescent Biopharma, Inc. (CBIO) vs Oculis Holding AG (OCS)

Crescent Biopharma, Inc. and Oculis Holding AG are both Biotechnology companies. Crescent Biopharma, Inc. and Oculis Holding AG are of similar size ($463.6M and $456.8M). Oculis Holding AG grew revenue faster over the last twelve months: 65.8% against −45.1%. Crescent Biopharma, Inc. has the higher net margin (0.00% vs −6,870.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Crescent Biopharma, Inc. leads on 8 and Oculis Holding AG on 8.

Valuation

Metric CBIO OCS Biotechnology median
P/E n/m n/m 8.50
P/S 296.75 303.32 9.71
P/B 2.27 1.61 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 186.66 108.92 9.21
Earnings yield (56.76%) (23.87%) (33.15%)
Free cash flow yield (19.88%) (18.51%) (25.50%)

Profitability

Metric CBIO OCS Biotechnology median
Gross margin 19.72% 100.00% 65.16%
Operating margin 0.00% (7,383.66%) 0.00%
Net margin 0.00% (6,870.05%) 0.00%
Free cash flow margin 0.00% (5,525.64%) 0.00%
Return on equity (112.14%) (44.87%) (56.36%)
Return on assets (97.08%) (37.69%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CBIO OCS Biotechnology median
Revenue growth (TTM) (45.09%) 65.83% 6.02%
EPS growth (last fiscal year) 44.97% 5.39% 30.26%
Revenue growth, 5-year CAGR 257.77% — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric CBIO OCS Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 9.66 8.35 4.72
Net debt to EBITDA 1.40 2.60 0.96

Dividend

Metric CBIO OCS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CBIO OCS Biotechnology median
Market cap 463.56m 456.82m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack